| scholarly article | Q13442814 |
| P50 | author | Zejun Fang | Q50084464 |
| P2093 | author name string | Rongwei Zhang | |
| Yanyan Hu | |||
| Chaoju Gong | |||
| Fuzheng Tao | |||
| Lingming Mei | |||
| Miaoxian Hu | |||
| Shenghui Ruan | |||
| P2860 | cites work | FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance | Q26864654 |
| Diversity of gene expression in adenocarcinoma of the lung | Q29616070 | ||
| TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion | Q33598619 | ||
| The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development | Q33613335 | ||
| Non–Small Cell Lung Cancer | Q34129295 | ||
| TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling | Q35040029 | ||
| Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis | Q35227377 | ||
| Glucose-6-phosphate dehydrogenase, NADPH, and cell survival | Q35886019 | ||
| OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance | Q36165185 | ||
| Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance | Q36392145 | ||
| Roles of HMGA proteins in cancer | Q37001370 | ||
| HMGA molecular network: From transcriptional regulation to chromatin remodeling | Q37592470 | ||
| Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer. | Q37698720 | ||
| TGF-β signalling and its role in cancer progression and metastasis | Q38020111 | ||
| Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling | Q38724559 | ||
| Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design | Q38730533 | ||
| Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis | Q38731433 | ||
| FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway | Q38922674 | ||
| FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients | Q39239961 | ||
| Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity | Q39523446 | ||
| Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase | Q40700999 | ||
| The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells | Q40996773 | ||
| TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer | Q41481557 | ||
| ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway | Q46255272 | ||
| The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance | Q47359487 | ||
| TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements | Q47792704 | ||
| Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System | Q49441931 | ||
| TGFβ pathway inhibition in the treatment of non-small cell lung cancer | Q50054712 | ||
| NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling | Q50084400 | ||
| FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells | Q50152457 | ||
| Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFβ1 signaling loop in esophageal squamous cell carcinoma. | Q51370517 | ||
| FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway. | Q51573165 | ||
| ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG. | Q54211934 | ||
| Targeting Forkhead Box M1 Transcription Factor in Breast Cancer. | Q54977309 | ||
| Involvement of FoxM1 in non-small cell lung cancer recurrence | Q85492085 | ||
| Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer | Q85853672 | ||
| Recent clinical advances in lung cancer management | Q87355242 | ||
| ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells | Q90277883 | ||
| The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer | Q91449607 | ||
| P433 | issue | 11 | |
| P921 | main subject | cisplatin | Q412415 |
| non-small-cell lung carcinoma | Q3658562 | ||
| P304 | page(s) | 6860-6876 | |
| P577 | publication date | 2019-11-15 | |
| P1433 | published in | American Journal of Translational Research | Q4744272 |
| P1476 | title | The TGFβ1-FOXM1-HMGA1-TGFβ1 positive feedback loop increases the cisplatin resistance of non-small cell lung cancer by inducing G6PD expression | |
| P478 | volume | 11 |
| Q89550697 | The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance | cites work | P2860 |
Search more.